BLAINJECTIONINJECTABLE
Approved
Jan 2026
Lifecycle
Launch
Competitive Pressure
30/100
Data completeness
2/8 — Basic
FILKRI (filgrastim-laha) by Accord Biopharma is colony-stimulating factors are glycoproteins which act on hematopoietic cells by binding to specific cell surface receptors and stimulating proliferation‚ differentiation commitment‚ and some end-cell functional activation. First approved in 2026.
Drug data last refreshed 8h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FILKRI is a biosimilar filgrastim (filgrastim-laha) developed by Accord Biopharma, approved in January 2026. It is a granulocyte colony-stimulating factor (G-CSF) that stimulates neutrophil production in the bone marrow by binding to specific cell surface receptors and promoting proliferation and differentiation. It is administered by injection and is indicated for patients requiring neutrophil support, typically those undergoing chemotherapy or with hematologic disorders.
Launch
As a newly launched biosimilar entering a mature market, FILKRI faces moderate competitive pressure (30/100) and will require focused market access and managed care teams to establish formulary positioning.
Mechanism of Action
Colony-stimulating factors are glycoproteins which act on hematopoietic cells by binding to specific cell surface receptors and stimulating proliferation‚ differentiation commitment‚ and some end-cell functional activation. Endogenous G-CSF is a lineage-specific colony-stimulating factor that is…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
FILKRI represents a launch-stage biosimilar opportunity with emphasis on commercial strategy, managed care navigation, and competitive pricing positioning. Roles will focus on market share capture in an established G-CSF market rather than clinical development or expansion.
Worked on FILKRI at Accord Biopharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.